Profile data is unavailable for this security.
About the company
IOL Chemicals and Pharmaceuticals Limited is engaged in manufacturing and selling of pharmaceutical and chemical products. The Company operates through two segments: Chemical and Pharmaceutical. The Chemical segment produces and sells Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride, Mono Chloro Acetic Acid, Para Amino Phenol (PAP), and others. The Pharmaceutical segment produces and sells various active pharma ingredients (API) including Ibuprofen, Metformin, Fenofibrate, Lamotrigine, Clopidogrel Bisulphate, Pantoprazole, Gabapentin, Paracetamol, and others. Its API product portfolio includes Pantoprazole Sodium, Clopidogrel Bisulphate (Form II), Losartan Potassium, Levetiracetam, and Fenofibrate (Micronised). Its Specialty Chemical division includes Ethyl Acetate, Iso Butyl Benzene, Mono Chloro acetic Acid, and Acetic Anhydride. Its Ethyl Acetate is used in industries like flexible packaging, pharmaceuticals, ink, food processing, pesticides, and the paint industry.
- Revenue in INR (TTM)21.70bn
- Net income in INR1.16bn
- Incorporated1986
- Employees2.89k
- LocationIOL Chemicals and Pharmaceuticals Ltd85, Industrial Area, 'A',LUDHIANA 141003IndiaIND
- Phone+91 1 612225531
- Fax+91 1 612608784
- Websitehttps://www.iolcp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 13.71bn | 456.00 | 38.76 | -- | 25.76 | 3.07 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Beta Drugs Ltd | 3.86bn | 464.68m | 14.26bn | 399.00 | 20.26 | 6.45 | 23.28 | 3.70 | 69.72 | 65.19 | 509.33 | 218.94 | 0.986 | 3.64 | 3.48 | 9,665,303.00 | 11.88 | 15.08 | 16.29 | 21.53 | 39.79 | 40.30 | 12.05 | 12.72 | 2.45 | 5.13 | 0.3974 | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Amrutanjan Health Care Ltd | 4.88bn | 569.03m | 18.29bn | 631.00 | 32.14 | -- | 28.92 | 3.75 | 19.68 | 19.68 | 168.85 | -- | -- | -- | -- | 7,736,897.00 | -- | 15.84 | -- | 19.67 | 50.87 | 52.17 | 11.66 | 13.26 | -- | 319.69 | -- | 19.82 | 7.26 | 11.56 | 13.03 | 15.17 | 69.46 | 26.76 |
| Windlas Biotech Ltd | 8.30bn | 673.21m | 18.37bn | 1.35k | 27.41 | 3.42 | 18.81 | 2.21 | 31.79 | 31.79 | 392.02 | 254.82 | 1.06 | 6.73 | 4.32 | 6,167,994.00 | 8.62 | 8.65 | 13.24 | 11.81 | 38.24 | 34.09 | 8.11 | 7.70 | 1.80 | 15.42 | 0.0552 | 18.33 | 20.43 | 18.24 | 4.82 | 30.34 | 27.99 | -- |
| Indoco Remedies Ltd | 17.58bn | -1.14bn | 18.91bn | 6.05k | -- | -- | 295.94 | 1.08 | -12.52 | -12.52 | 197.86 | -- | -- | -- | -- | 2,905,519.00 | -- | 4.84 | -- | 6.87 | 71.18 | 65.70 | -6.62 | 5.16 | -- | -0.3334 | -- | 17.11 | -8.38 | 8.51 | -174.89 | -- | 43.53 | -7.79 |
| Solara Active Pharma Sciences Ltd | 12.06bn | 64.10m | 21.13bn | 1.78k | 398.88 | 1.83 | 20.45 | 1.75 | 1.20 | 1.20 | 325.96 | 261.13 | 0.5263 | 1.68 | 3.32 | 6,794,423.00 | 0.2797 | -3.27 | 0.4821 | -5.35 | 54.11 | 39.95 | 0.5315 | -6.17 | 0.4929 | 0.9751 | 0.3394 | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| Bliss GVS Pharma Ltd | 8.60bn | 1.10bn | 21.54bn | 966.00 | 19.74 | 1.90 | 14.61 | 2.50 | 10.31 | 10.31 | 80.97 | 107.18 | 0.6414 | 3.38 | 1.87 | 8,905,504.00 | 8.60 | 6.04 | 10.41 | 7.54 | 50.76 | 46.33 | 13.42 | 9.45 | 3.86 | 8.37 | 0.043 | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Morepen Laboratories Ltd | 17.55bn | 986.27m | 21.65bn | 1.81k | 21.89 | 1.81 | 15.34 | 1.23 | 1.80 | 1.80 | 32.16 | 21.83 | 1.06 | 4.24 | 6.12 | 9,677,225.00 | 6.03 | 8.14 | 8.20 | 12.81 | 33.02 | 31.83 | 5.67 | 5.91 | 1.65 | 6.43 | 0.1169 | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Hikal Ltd | 16.99bn | 101.00m | 22.62bn | 2.06k | 223.28 | 1.89 | 14.00 | 1.33 | 0.8216 | 0.8216 | 137.81 | 96.86 | 0.7065 | 2.01 | 4.59 | 8,239,573.00 | 0.42 | 4.78 | 0.6016 | 7.00 | 55.49 | 48.00 | 0.5945 | 5.71 | 0.5418 | 1.11 | 0.3639 | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Panacea Biotec Ltd | 6.04bn | -72.40m | 22.70bn | 1.29k | -- | 2.75 | 86.51 | 3.76 | -1.18 | -1.18 | 98.44 | 134.92 | 0.4836 | 1.38 | 8.67 | 4,681,039.00 | -0.6085 | 13.08 | -0.8291 | 19.61 | 58.47 | 48.06 | -1.26 | 30.99 | 0.9785 | -14.33 | 0.0271 | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 21.70bn | 1.16bn | 22.95bn | 2.89k | 19.80 | 1.31 | 11.90 | 1.06 | 3.95 | 3.95 | 73.97 | 59.66 | 0.9278 | 3.77 | 4.39 | 7,507,091.00 | 4.95 | 10.26 | 6.48 | 13.42 | 34.01 | 32.57 | 5.34 | 9.33 | 1.32 | 9.37 | 0.0832 | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 27.91bn | 3.33k | 9.48 | -- | 6.66 | 1.26 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| SMS Pharmaceuticals Ltd | 8.60bn | 843.60m | 29.99bn | 1.47k | 33.05 | 4.11 | 25.39 | 3.49 | 9.69 | 9.69 | 98.93 | 77.88 | 0.7134 | 1.82 | 3.96 | 5,850,513.00 | 6.72 | 5.58 | 9.76 | 7.66 | 33.05 | 33.78 | 9.42 | 8.05 | 0.916 | 5.98 | 0.3078 | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
| Gufic BioSciences Ltd | 8.74bn | 569.19m | 31.43bn | 1.99k | 55.19 | 4.98 | 37.03 | 3.60 | 5.68 | 5.68 | 87.10 | 62.94 | 0.7354 | 1.87 | 2.75 | 4,394,322.00 | 4.79 | 10.27 | 7.34 | 16.11 | 55.47 | 46.41 | 6.52 | 10.48 | 1.06 | 3.13 | 0.3691 | 1.31 | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
Data as of Feb 10 2026. Currency figures normalised to IOL Chemicals and Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
1.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 2.63m | 0.90% |
| American Century Investment Management, Inc.as of 08 Jan 2026 | 801.54k | 0.27% |
| Mellon Investments Corp.as of 09 Jan 2026 | 339.82k | 0.12% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 189.90k | 0.07% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 151.12k | 0.05% |
| DFA Australia Ltd.as of 31 Dec 2025 | 31.08k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 3.65k | 0.00% |
| Bandhan AMC Ltd.as of 31 Dec 2025 | 1.45k | 0.00% |
More ▼
Data from 30 Sep 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
